apremilast oral psoriasis
Selected indexed studies
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (J Am Acad Dermatol, 2023) [PMID:35820547]
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (J Am Acad Dermatol, 2015) [PMID:26089047]
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (JAMA, 2020) [PMID:32427307]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. (2023) pubmed
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (2023) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials. (2023) pubmed
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (2015) pubmed
- Oral Psoriasis Therapies. (2024) pubmed
- Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. (2018) pubmed
- Oral Apremilast for the Treatment of Plaque Psoriasis. (2016) pubmed
- Psoriasis. (2025) pubmed